GlassScriptPhysician profile
Samuel Joseph Needles
NPI 1396276283
$959.74
in general payments reported to CMS, 2019-2025
14 companies · $491 in 2025
The $491 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $183 · 2024: $178 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $265.34 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $128.94 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $109.70 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Abbvie INC. | $102.05 | 2023 | |
| Sumitomo Pharma America, INC. | $84.26 | 2025 | Myfembree |
| Pfizer INC. | $50.01 | 2022-2023 | |
| Exeltis, USA INC. | $44.52 | 2025 | Slynd |
| Mayne Pharma Commercial LLC | $34.87 | 2023-2025 | |
| Dexcom, INC. | $33.27 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $26.09 | 2023 | Truclear |
| Meditrina | $20.79 | 2025 | |
| Organon LLC | $20.28 | 2024 | |
| Millicent US INC | $20.12 | 2025 | Intrarosa, Femlyv |
| Shield Therapeutics INC | $19.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Needles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.